Patents by Inventor Sabine Pirotton
Sabine Pirotton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210123905Abstract: A method for the evaluation of a hydrolyzed allergen preparation comprising the steps of: bringing the preparation into contact with a human blood sample—measuring proliferation of IL10 producing regulatory B-cells, wherein proliferation indicates suitability of the preparation.Type: ApplicationFiled: April 30, 2019Publication date: April 29, 2021Applicant: ASIT BIOTECH SAInventors: Cecile Pâques, Thierry Legon, Sabine Pirotton, Nicolas Bovy
-
Publication number: 20180256708Abstract: A method for the production of a purified extract of natural allergens comprising the steps of a) extracting a natural source of allergens comprising allergenic proteins to form an extract, b) purifying of said extract to remove non-protein components to form a purified extract c) denaturating said purified extract to form a purified denaturated extract, said purified denaturated extract comprising proteins, wherein the most abundant (w/w) proteins, forming together at least 60% (w/w) of all proteins, are at least two proteins, and all proteins represent at least 60% (w/w) of the dry weight of the purified denaturated extract and a method for the production of a purified extract of natural allergens comprising the steps of a) hydrolysing a denaturated allergen to form an allergen hydrolysate, b) purifying said allergen hydrolysate to remove peptides with a molecular weight above 10,000 Da and below 1,000 Da in order to obtain a purified hydrolysate where 70%, more preferably 80% of the peptides are betweType: ApplicationFiled: May 9, 2018Publication date: September 13, 2018Applicant: Biotech Tools S.A.Inventors: Thierry LEGON, Sabine PIROTTON, Gael PLACIER, Gilles KERGOAT
-
Publication number: 20170100476Abstract: A pharmaceutical preparation comprising—10 to 200 ?g/ml of fragments of an antigenic structure which induces allergic reaction—2 to 6% (w/v) mannitol—0.5 to 2% (w/v) trehalose—water, wherein said preparation essentially does not comprise heat shock proteins.Type: ApplicationFiled: April 9, 2015Publication date: April 13, 2017Inventors: Thierry Legon, Sabine Pirotton, Gael Placier
-
Publication number: 20140255449Abstract: A pharmaceutical preparation for subcutaneous injection comprising between 0.5 ng and 200 ?g of HSP70 between 0.5 and 100 ?g of fragments of an antigenic structure.Type: ApplicationFiled: July 19, 2012Publication date: September 11, 2014Applicant: BioTech Tools S.A.Inventors: Thierry Legon, Sabine Pirotton, Jean Duchateau
-
Patent number: 8735122Abstract: Recombinant purified DnaK—having a ATPase activity without the addition of an other chaperone protein—essentially free of T-cell stimulating impurities.Type: GrantFiled: October 12, 2007Date of Patent: May 27, 2014Assignee: Biotech Tools S.A.Inventors: Frederic Henot, Thierry Legon, Sabine Pirotton, Gael Placier
-
Publication number: 20100278880Abstract: Method for the production of a purified extract of natural allergens comprising the steps of extracting a natural source of allergens comprising allergenic proteins, purifying of said extract to remove non-protein components denaturating said purified extract, said purified denaturated extract comprising proteins, wherein the most abundant (w/w) proteins, forming together at least 60% (w/w) of all proteins, are at least two proteins, and all proteins represent at least 60% (w/w) of the dry weight of the purified denaturated extract or a method for the production of a purified extract of natural allergens comprising the steps of hydrolysing a denaturated allergen purifying said allergen hydrolysate to remove peptides with a molecular weight above 10,000 Da and below 1,000 Da in order to obtain a purified hydrolysate where 70%, more preferably 80% of the peptides are between 10,000 Da and 1,000 Da, in the form of an starch based pellet.Type: ApplicationFiled: December 30, 2008Publication date: November 4, 2010Inventors: Thierry Legon, Sabine Pirotton, Gael Placier, Gilles Kergoat
-
Publication number: 20090324650Abstract: A method for the production of a purified extract of natural allergens comprising the steps of a) extracting a natural source of allergens comprising allergenic proteins to form an extract, b) purifying of said extract to remove non-protein components to form a purified extract c) denaturating said purified extract to form a purified denaturated extract, said purified denaturated extract comprising proteins, wherein the most abundant (w/w) proteins, forming together at least 60% (w/w) of all proteins, are at least two proteins, and all proteins represent at least 60% (w/w) of the dry weight of the purified denaturated extract and a method for the production of a purified extract of natural allergens comprising the steps of a) hydrolysing a denaturated allergen to form an allergen hydrolysate, b) purifying said allergen hydrolysate to remove peptides with a molecular weight above 10,000 Da and below 1,000 Da in order to obtain a purified hydrolysate where 70%, more preferably 80% of the peptides are betweType: ApplicationFiled: June 28, 2007Publication date: December 31, 2009Inventors: Thierry Legon, Sabine Pirotton, Gael Placier, Gilles Kergoat
-
Patent number: 7312317Abstract: This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according to the invention in presence of these agonists presents a functional response (preferably the accumulation of Inositol triphosphate (IP3), diacylglycerol (DAG), or calcium ions) to lower concentration of pyrimidine nucleotides, preferably uridine triphosphate, than to purine nucleotides or a more important functional response to similar concentration of pyrimidine nucleotide than to purine nucleotide.Type: GrantFiled: March 26, 2004Date of Patent: December 25, 2007Assignee: Euroscreen s.a.Inventors: Didier Communi, Jean-Marie Boeynaems, Marc Parmentier, Sabine Pirotton
-
Patent number: 7270966Abstract: This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent.Type: GrantFiled: January 8, 2004Date of Patent: September 18, 2007Assignee: Euroscreen SAInventors: Didier Communi, Marc Parmentier, Jean-Marie Boeynaems, Sabine Pirotton
-
Publication number: 20070044166Abstract: This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent.Type: ApplicationFiled: July 7, 2006Publication date: February 22, 2007Inventors: Didier Communi, Sabine Pirotton, Marc Parmentier, Jean-Marie Boeynaems
-
Publication number: 20040268426Abstract: This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent.Type: ApplicationFiled: March 26, 2004Publication date: December 30, 2004Applicant: Euroscreen, s.a.Inventors: Didier Communi, Sabine Pirotton, Marc Parmentier, Jean-Marie Boeynaems
-
Publication number: 20040259171Abstract: This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent.Type: ApplicationFiled: March 26, 2004Publication date: December 23, 2004Applicant: Euroscreen, s.a.Inventors: Didier Communi, Sabine Pirotton, Marc Parmentier, Jean-Marie Boeynaems
-
Patent number: 6790626Abstract: The present invention concerns a new receptor having a preference for pyrimidine nucleotides, preferably UTP, or purine nucleotides and UDP, and which has an amino acid sequence having more than 60% homology with the amino acid sequence shown in FIG. 1.Type: GrantFiled: November 12, 1998Date of Patent: September 14, 2004Assignee: Euroscreen S.A.Inventors: Didier Communi, Sabine Pirotton, Marc Parmentier, Jean-Marie Boeynaems
-
Publication number: 20040175766Abstract: This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent.Type: ApplicationFiled: January 8, 2004Publication date: September 9, 2004Applicant: Euroscreen, s.a.Inventors: Didier Communi, Sabine Pirotton, Marc Parmentier, Jean-Marie Boeynaems
-
Publication number: 20030082674Abstract: This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphopshate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according to the invention in presence of these agonists presents a functional response (preferably the accumulation of Inositol triphosphate (IP3), diacylglycerol (DAG), or calcium ions) to lower concentration of pyrimidine nucleotides, preferably uridine triphopshate, than to purine nucleotides or a more important functional response to similar concentration of pyrimidine nucleotide than to purine nucleotide.Type: ApplicationFiled: November 12, 1998Publication date: May 1, 2003Inventors: DIDIER COMMUNI, SABINE PIROTTON, MARC PARMENTIER, JEAN-MARIE BOEYNAEMS